Labiotech.eu

News and Trends 31 Jan 2017

New British Biotech-Academia Alliance takes on Cardiovascular Disease

Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based in London, develops drugs against historically undruggable G protein-coupled receptors (GPCRs). The company has now announced a new research collaboration with the University of Cambridge focusing on a specific GPCR, the apelin receptor. Heptares will support a […]

January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Jan 2017

Top 5 Biologicals from European Biopharma to Launch in 2017

A new report listing the top drug launches this year reveals the strong performance of biologicals and European biopharma on the drug market. After the worst year in biotech finance, experts seem to agree that the industry will start recovering in 2017. There are still substantial uncertainties, mostly regarding the new US administration. Though a […]

January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 31 Jan 2017

Biologicals on the Brain: Biotech in Neurodegenerative Disease

Brain diseases are hard to treat, but biotechs are harnessing a variety of techniques, including immunotherapy and gene therapy, to target neurodegenerative disorders. When Eli Lilly announced that solanezumab, a long anticipated Alzheimer’s antibody, failed in their third attempt at a late stage trial last year, it crushed patients’ hopes and raised doubts about whether […]

January 31, 2017 - 7 minutesmins - By Diana Kwon

News and Trends 30 Jan 2017

Novo Nordisk will open a €135M Diabetes R&D Center at Oxford University

A new research center funded by Novo Nordisk will foster collaborations between its staff and researchers from the University of Oxford. Novo Nordisk and the University of Oxford have announced a collaboration focused on type 2 diabetes research. As part of the effort, the Danish pharma will invest €135M (£115M) over a 10-year period to […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Jan 2017

The FDA gives Fast Track Priority to uniQure’s Hemophilia B Gene Therapy

UniQure has received Breakthrough Therapy Designation from the FDA, granting fast track to its gene therapy for hemophilia B. UniQure is one of the companies leading the development of gene therapy for hemophilia. Now, the FDA has granted Breakthrough Therapy Designation to its candidate AMT-060 for hemophilia B. This is awarded to selected therapies that have […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Jan 2017

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small size and high solubility. The company has now received a milestone payment from Danish pharma Lundbeck for the development of the technology as a delivery […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 30 Jan 2017

The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge

Cambridge’s image is tied to its Hogwarts-like University and Nobel-hoarding academia, but there’s also an exciting entrepreneurial scene at the cutting edge of technology. We took a look at how big biotech is in the Silicon Fen. Cambridge’s Biotech cluster has an exemplary hive of talent, infrastructure, and capital – enough to create the same vibe […]

January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro

More News! 28 Jan 2017

Microbes Control the Massive Turbine Hall at London’s Tate Modern

Philippe Parreno’s Anywhen, occupying the vast hall at Tate Modern, evolves over time in response to the control of tiny living beings. When you enter Tate Modern‘s vast Turbine Hall, you might see lights turning off and on and hear noises coming and going. Without an apparent pattern, sounds and light evolve while families take […]

January 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 27 at 2.17.05 PM 1 e1485524200727

Startup Scout 27 Jan 2017

Needle-free Treatments for Autoimmune Disorders from Switzerland

It’s back to go back to the mainland. This week’s stop is in Hergiswill, a city by one of the many beautiful seas that can be found in Switzerland. There, the young biotech BioLingus is developing needle-free therapies for chronic diseases. City: Hergiswill, Switzerland Founded: 2014 Employees: 1-10 Financial data: N/A Mission: BioLingus develops non-invasive treatments for autoimmune and inflammatory […]

January 27, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 27 Jan 2017

Bad News for Diabetics: Eli Lilly Abandons French Ultra-Rapid Insulin

Eli Lilly has decided to terminate its partnership with Adocia for the development of BioChaperone Lispro, an ultra-rapid insulin for diabetes. Despite results from 6 clinical studies indicating that Adocia’s ultra-rapid insulin performs better than Eli Lilly’s Humalog, the big American pharma has decided to terminate its collaboration with the French biotech. As part of this […]

January 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Jan 2017

Researchers are One Step Closer to Understanding Artificial Silk

Silk is a material in high demand, and so is a method to produce it artificially. A Swedish-German team of researchers is studying how to make silk with milk whey protein. Besides making way for a potentially cheaper process, artificial silk could have important medical applications. Researchers from the Royal Institute of Technology (KTH) in Stockholm and […]

January 27, 2017 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 26 Jan 2017

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline will be spun out into a new Switzerland-based outfit. The wait is over folks: Actelion, the largest biotech in Europe and one of the only 9 to make it to the billion-euro club in 2016, has just announced its acquisition by Johnson & Johnson for a […]

January 26, 2017 - 2 minutesmins - By Evelyn Warner

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

New British Biotech-Academia Alliance takes on Cardiovascular Disease

Top 5 Biologicals from European Biopharma to Launch in 2017

Biologicals on the Brain: Biotech in Neurodegenerative Disease

Novo Nordisk will open a €135M Diabetes R&D Center at Oxford University

The FDA gives Fast Track Priority to uniQure’s Hemophilia B Gene Therapy

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge

Microbes Control the Massive Turbine Hall at London’s Tate Modern

Needle-free Treatments for Autoimmune Disorders from Switzerland

Bad News for Diabetics: Eli Lilly Abandons French Ultra-Rapid Insulin

Researchers are One Step Closer to Understanding Artificial Silk

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!